.jpg?format=webp&width=780)
The prognosis for lupus nephritis (LN) has not improved significantly despite the development of immunomodulatory agents and supportive care. End-stage kidney disease still affects 5-30% of patients within 10 years of diagnosis. Treatment prioritization varies due to inter-ethnic variation in clinical response and evidence for various therapies. There is a need for modalities that better preserve kidney function and reduce glucocorticoid toxicity. Newly approved and investigational drugs, including newer generation calcineurin inhibitors and biologic agents, are being developed. Clinical considerations and patient stratification are important in choosing therapies, and molecular profiling and urine proteomic panels may enhance treatment personalization in the future.
Like
Save
Share